Oncology

Print

Explora’s senior management has decades of industry experience in cancer drug development. Our scientists routinely conduct contract research using xenograft models for industry as well as academic scientists. We also maintain rigorous cell culture procedures to ensure consistency in the quality of our cell lines.

Explora’s research team has:

  • Sound knowledge of tumor biology and immuno-oncology
  • Extensive experience in oncology drug development
  • Excellent technical and surgical capability
  • Established IACUC protocols

We can assist with the following:

Sample tumor growth curve

Sample tumor growth curve

  • Model selection and study design
  • In vivo drug screening
  • Mechanistic studies
  • General technical reports (GTR) generation for IND filing
  • On-site technical support and training

Cancer Xenograft Efficacy Models

Explora has experience with many oncology animal models used to test anti-cancer therapies, including the following:

  • Subcutaneous xenograft models (usually human tumors or cell lines transplanted into immuno-compromised rodents).
  • NCI-60 cancer cell lines (over 45 lines characterized in-house for tumorigenicity)
  • Patient-derived xenograft (PDX) models from multiple sources
  • Commercial or client-produced cell lines
  • Orthotopic tumor models, which are cells implanted directly into organs of interest.
  • Renal capsule, mammary fat pad (mfp) and spleen implantation
  • Prostate, ovarian models
  • Brain tumor model
  • Metastatic models
    • Forced metastatic models
    • Spontaneous metastatic models
  • Hu-SCID models, which are used with human immune system substitution for development of antibody therapy and immunotherapy.
  • Syngeneic models, including B16 melanoma and Lewis lung carcinoma (LLC)

Assays and Endpoints

Explora can help you obtain high-quality, meaningful data from every study. Common assays and endpoints in oncology studies include:

  • Tumor size reduction and remission
  • Tumor growth delay
  • Decrease in metastases
  • Drug effects on host and tumor
  • Increase in lifespan of the host
  • Changes in biomarkers